Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States.
Antimicrob Resist Infect Control
; 6: 107, 2017.
Article
em En
| MEDLINE
| ID: mdl-29090091
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Guideline
/
Health_economic_evaluation
/
Prognostic_studies
/
Risk_factors_studies
/
Screening_studies
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article